Literature DB >> 7524767

Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.

M Maier-Redelsperger1, C T Noguchi, M de Montalembert, G P Rodgers, A N Schechter, A Gourbil, D Blanchard, J P Jais, R Ducrocq, J Y Peltier.   

Abstract

Intracellular hemoglobin S (HbS) polymerization is most likely to be the primary determinant of the clinical and biologic manifestations of sickle cell disease (SCD). Fetal hemoglobin (HbF) does not enter the HbS polymer and its intracellular expression in sickle erythrocytes inhibits polymerization. HbF levels, high at birth but decreasing thereafter, protect the newborn from the clinical manifestations of this hemoglobinopathy. We have measured the sequential changes in HbF, F reticulocytes, and F cells in the first 2 years of life in 25 children with SCD and compared the results with those obtained in 30 normal children (AA). We have also calculated HbF per F cell (F/F cell), the preferential survival of F cells versus non-F cells, as measured by the ratio F cells versus F reticulocytes (FC/FR) and polymer tendency at 40% and 70% oxygen saturation. HbF levels decreased from about 80.4% +/- 4.0% at birth to 9.2% +/- 2.9% at 24 months. During this time, we observed a regular decrease of the F reticulocytes and the F cells. The kinetics of the decline of F/F cell was comparable with the decline of HbF, rapid from birth (mean, 27.0 +/- 3.6 pg) to 12 months of age (mean, 8.5 +/- 1.5 pg) and then slower from 12 to 24 months of age (mean, 6.2 +/- 1.0 pg) in the SCD children. In the AA children, the decrease in HbF, due to changes in both numbers of F cells and F/F cell, was more precipitous, reaching steady-state levels by 10 months of age. Calculated values for mean polymer tendency in the F-cell population showed that polymerization should begin to occur at 40% oxygen saturation at about 3 months and increase progressively with age, whereas polymerization at 70% oxygen saturation would not occur until about 24 months. These values correspond to HbF levels of 50.8% +/- 10.8% and 9.2% +/- 2.9%, respectively, and F/F cell levels of 15.6 +/- 4.5 pg and 6.2 +/- 1.0 pg, respectively. In the non--F-cell population, polymerization was expected at birth at both oxygen saturation values. Three individuals had significantly greater predicted polymerization tendency than the remainder of the group because of early decreases in HbF. These individuals in particular, the remainder of the cohort, as well as other recruited newborns, will be studied prospectively to ascertain the relationship among hematologic parameters, which determine polymerization tendency and the various clinical manifestations of SCD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524767

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis.

Authors:  C Antwi-Boasiako; E Frimpong; G K Ababio; B Dzudzor; I Ekem; B Gyan; N A Sodzi-Tettey; D A Antwi
Journal:  Ghana Med J       Date:  2015-06

2.  A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.

Authors:  Ajay Perumbeti; Tomoyasu Higashimoto; Fabrizia Urbinati; Robert Franco; Herbert J Meiselman; David Witte; Punam Malik
Journal:  Blood       Date:  2009-05-27       Impact factor: 22.113

Review 3.  Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.

Authors:  Alawi H Habara; Elmutaz M Shaikho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

4.  Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain.

Authors:  Maha Khaleel; Mammen Puliyel; Payal Shah; John Sunwoo; Roberta M Kato; Patjanaporn Chalacheva; Wanwara Thuptimdang; Jon Detterich; John C Wood; Jennie Tsao; Lonnie Zeltzer; Richard Sposto; Michael C K Khoo; Thomas D Coates
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

Review 5.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

6.  Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease.

Authors:  David Calvet; Titien Tuilier; Nicolas Mélé; Guillaume Turc; Anoosha Habibi; Nassim Ait Abdallah; Loubna Majhadi; François Hemery; Myriam Edjlali; Frédéric Galacteros; Pablo Bartolucci
Journal:  Blood Adv       Date:  2017-12-01

7.  Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood.

Authors:  Emily Riehm Meier; Colleen Byrnes; Maxine Weissman; Pierre Noel; Naomi L C Luban; Jeffery L Miller
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

Review 8.  Sickle cell disease in children.

Authors:  Emily Riehm Meier; Jeffery L Miller
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

9.  Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.

Authors:  R Borba; C S P Lima; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

10.  Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign.

Authors:  Abdulrahman Alsultan; Mohammed K Alabdulaali; Paula J Griffin; Ahmed M Alsuliman; Hazem A Ghabbour; Paola Sebastiani; Waleed H Albuali; Amein K Al-Ali; David H K Chui; Martin H Steinberg
Journal:  Br J Haematol       Date:  2013-11-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.